Last updated: September 9, 2026

Chloroquine phosphate and primaquine phosphate are mature, low-cost antimalarial medicines with no meaningful remaining composition-patent protection. Their commercial value comes from public-health procurement, endemic-country demand, hospital stockpiling, and periodic supply shortages rather than branded pricing power. Chloroquine has lost most demand in regions where malaria parasites have developed resistance, while primaquine remains clinically important for preventing relapse from Plasmodium vivax and Plasmodium ovale infections.

Neither drug has a transparent, separately reported global revenue stream. Public company filings generally aggregate these products within broader pharmaceutical or established-products portfolios. The financial outlook is therefore best assessed through demand drivers, regulatory status, supplier concentration, procurement economics, and generic-entry risk.

What are chloroquine phosphate and primaquine phosphate used for?

Chloroquine phosphate is an antimalarial drug used against susceptible malaria parasites and for certain non-malarial indications. Its malaria utility is constrained by widespread resistance in Plasmodium falciparum and resistance in some P. vivax regions. The U.S. FDA-approved label includes treatment and suppression of malaria caused by susceptible strains, as well as extraintestinal amebiasis and certain lupus-related indications under the product labeling framework [1].

Primaquine phosphate is used primarily for radical cure of P. vivax and P. ovale malaria. It eliminates dormant liver-stage hypnozoites that can cause recurrent infection. Primaquine is not interchangeable with chloroquine because the two drugs address different parts of the parasite life cycle. Primaquine use requires attention to glucose-6-phosphate dehydrogenase, or G6PD, status because the drug can cause hemolytic anemia in deficient patients [2].

Product	Active ingredient	Principal malaria role	Main commercial limitation
Chloroquine phosphate	Chloroquine phosphate	Blood-stage treatment for susceptible malaria	Parasite resistance and low pricing
Primaquine phosphate	Primaquine phosphate	Radical cure and relapse prevention for P. vivax and P. ovale	G6PD safety screening and limited volume

The products are often discussed together in malaria treatment protocols, but they are separate drugs, separate dosage forms, and separate regulatory products.

How large is the market for chloroquine phosphate and primaquine phosphate?

The addressable market is fragmented and difficult to measure through public financial disclosures. Demand consists of several distinct segments:

Government malaria programs and international procurement.
Retail and hospital generic prescriptions.
Military and travel medicine.
Emergency stockpiles.
Institutional purchases in countries where malaria remains endemic.
Limited non-malarial use for chloroquine.

Chloroquine demand has declined over several decades as resistant parasites displaced it in many markets. The World Health Organization recommends artemisinin-based combination therapies for uncomplicated P. falciparum malaria in areas with chloroquine resistance, while chloroquine remains relevant in selected settings where susceptibility persists [3].

Primaquine has a smaller unit market but stronger clinical differentiation. It remains important for relapse prevention in P. vivax, particularly in Asia, Latin America, and parts of the Middle East. The drug's role is supported by the absence of many inexpensive alternatives with the same established use against hypnozoites. Tafenoquine competes in this segment but has higher access, prescribing, and diagnostic constraints in many markets.

There is no reliable public basis for assigning a precise global revenue figure to either active ingredient. Manufacturers generally report them as part of broad generic or established-medicines sales. Revenue estimates that present a single worldwide number should be treated cautiously unless they identify the covered countries, dosage forms, channels, and supplier set.

What is the financial trajectory for chloroquine phosphate?

Chloroquine phosphate has a structurally mature financial profile:

Period	Financial and demand trend
Pre-2020	Low-margin generic demand, concentrated in malaria-endemic markets and public procurement
2020	Temporary demand and inventory distortion linked to COVID-19 claims
2021 onward	Reversion toward conventional antimalarial demand after evidence failed to show clinical benefit in COVID-19
Current outlook	Stable but limited malaria demand, with upside mainly from supply disruptions or procurement changes

The COVID-19 period produced an abnormal demand spike. The FDA revoked the emergency use authorization for chloroquine phosphate and hydroxychloroquine sulfate products for COVID-19 treatment outside clinical trials in June 2020 after concluding that the statutory criteria for authorization were no longer met [4]. Randomized clinical evidence did not establish chloroquine as an effective COVID-19 treatment.

That episode created short-term inventory movements but did not produce durable pricing power. Chloroquine remains a low-price generic with limited ability to convert demand shocks into sustained margin expansion. Financial performance depends more on manufacturing continuity and procurement contracts than on prescription growth.

What drives chloroquine phosphate pricing?

Pricing is influenced by:

API availability and manufacturing concentration.
Country-specific tender prices.
Minimum purchase obligations in public-sector contracts.
Tablet strength and packaging requirements.
Quality-assurance and registration costs.
Freight and inventory costs.
Temporary shortages in approved suppliers.

The product can experience localized price increases during shortages, but substitution and generic competition constrain the duration of those increases. Chloroquine's low cost also limits the absolute revenue opportunity even when unit volumes are substantial.

What is the financial trajectory for primaquine phosphate?

Primaquine has a more defensible clinical position than chloroquine in relapse prevention, but its market remains small compared with high-volume antimalarial combinations. Its financial trajectory is likely to be relatively stable, with moderate demand growth tied to improved diagnosis and treatment of P. vivax rather than premium pricing.

The principal commercial variables are:

Expansion of malaria diagnosis in P. vivax regions.
Government adoption of radical-cure protocols.
Availability of G6PD testing.
Competition from tafenoquine.
Regulatory acceptance of low-cost generic tablets.
Procurement decisions by national malaria programs.

Primaquine's need for G6PD risk assessment can reduce prescribing where testing is unavailable. That restriction limits the conversion of epidemiological need into drug volume. It also creates a commercial opportunity for suppliers that can offer compatible testing, distribution, and training programs.

Tafenoquine may reduce the number of primaquine treatment courses in jurisdictions that approve and procure it. However, tafenoquine has its own limitations, including G6PD testing requirements, age and pregnancy restrictions, formulary acceptance, and higher acquisition cost in many markets. Primaquine is likely to remain the lower-cost default where health systems can manage its dosing and safety requirements.

What is the FDA regulatory and Orange Book status of these drugs?

Chloroquine phosphate and primaquine phosphate are legacy FDA-approved drug products, not new molecular entities with meaningful remaining regulatory exclusivity.

Drug	U.S. regulatory position	Dosage-form status	Exclusivity outlook
Chloroquine phosphate	FDA-approved prescription antimalarial product and generic equivalents	Tablets, including 250 mg and 500 mg strengths in the established product framework	No meaningful remaining NCE or market exclusivity
Primaquine phosphate	FDA-approved prescription antimalarial product	Tablets commonly labeled as 26.3 mg phosphate, equivalent to 15 mg base	No meaningful remaining NCE or market exclusivity

The FDA Orange Book identifies approved products and therapeutic-equivalence information, but legacy products such as these generally do not have active patent barriers comparable to newer branded drugs [5]. FDA labeling and Drugs@FDA records establish the approved uses, strengths, warnings, and sponsors for the relevant products [1, 6].

Neither product should be analyzed as a current patent-protected franchise. The principal regulatory barriers are abbreviated new drug application requirements, manufacturing compliance, bioequivalence, supply reliability, and market registration in each country.

What patents protect chloroquine phosphate and primaquine phosphate?

No commercially significant U.S. composition-of-matter patent protection remains for either active ingredient. Chloroquine was developed and commercialized in the mid-20th century, and primaquine was introduced in the 1950s. Any original compound patents expired many decades ago.

Patent category	Chloroquine phosphate	Primaquine phosphate
Original compound patent	Expired	Expired
Salt-form patent	No meaningful current barrier identified	No meaningful current barrier identified
U.S. Orange Book product patent	No material active barrier identified	No material active barrier identified
Formulation patent	Limited commercial relevance	Limited commercial relevance
Method-of-use patent	No meaningful current barrier for established malaria uses	No meaningful current barrier for established relapse-prevention use
Generic entry risk	High	High

Potentially relevant intellectual-property rights could still arise around packaging, manufacturing processes, diagnostic systems, fixed-dose combinations, or newer dosing regimens. Those rights would not restore exclusivity to the established active ingredients themselves unless they were narrow and commercially unavoidable.

When do chloroquine and primaquine lose exclusivity?

They lost practical exclusivity decades ago. The products are now in the post-patent generic phase.

The more relevant timeline is regulatory and commercial:

Original active-ingredient exclusivity: expired decades ago.
U.S. generic competition: established.
Orange Book patent protection: no material current barrier identified.
Paragraph IV litigation exposure: low.
Current competitive risk: manufacturing interruptions, procurement displacement, and therapeutic substitution.
Commercial risk: low unit pricing and limited branded differentiation.

A new entrant would generally compete through an ANDA or other applicable regulatory pathway, subject to FDA requirements and product-specific approval conditions. A Paragraph IV certification is possible as a legal mechanism, but there is little economic reason to expect substantial litigation over expired core compounds absent a newly listed patent covering a particular product or method.

Which companies are challenging the market, and what is the competitive landscape?

Competition is primarily from generic manufacturers, public-sector suppliers, and alternative antimalarial therapies rather than from branded patent challengers.

Chloroquine competitors

Chloroquine competes with:

Artemisinin-based combination therapies for P. falciparum.
Atovaquone-proguanil for travel medicine and selected treatment settings.
Mefloquine in prophylaxis and treatment markets.
Quinine or quinidine in limited clinical settings.
Hydroxychloroquine for selected non-malarial indications.

Hydroxychloroquine is chemically related but is not a direct substitute for every approved chloroquine use. The two products have different labeling, dosing, and regulatory histories.

Primaquine competitors

Primaquine competes with:

Tafenoquine for radical cure of P. vivax.
Country-specific treatment protocols that omit or delay radical cure.
Alternative public-health strategies that prioritize prevention and vector control.

Tafenoquine can reduce adherence problems because it may require a shorter course, but access to the drug and G6PD testing can limit adoption. Primaquine remains advantaged on price and historical availability.

What generic entry risks exist?

Generic-entry risk is high for both products because:

The active ingredients are old.
Core patents have expired.
The clinical products are conventional oral tablets.
There is no meaningful NCE exclusivity.
Therapeutic alternatives are available.
Procurement buyers are price-sensitive.

The principal risk for incumbent suppliers is not a patent-driven launch cliff. It is gradual price erosion, tender displacement, and loss of volume to suppliers with lower manufacturing or distribution costs.

For primaquine, supplier quality and regulatory reliability may matter more than nominal price. A procurement agency may prefer a higher-cost supplier if the product has dependable registration, validated manufacturing, and consistent delivery. That creates some protection from purely opportunistic entrants, but it does not create patent exclusivity.

What manufacturing and intellectual-property barriers affect supply?

Manufacturing barriers are practical rather than patent-based. Key requirements include:

GMP-compliant API and finished-dose production.
Stable tablet compression and content uniformity.
Validated dissolution and assay methods.
Qualified packaging for hot and humid climates.
Reliable supply of pharmaceutical-grade API.
Country-specific registration and pharmacovigilance.
Compliance with public-procurement quality standards.

Primaquine also carries a clinical implementation barrier because safe use depends on G6PD risk management. A supplier that supports testing access may gain procurement advantages, even without a protected formulation.

Chloroquine manufacturing is technically established, but market supply can still become fragile when few manufacturers maintain active registrations or when demand is concentrated in low-margin tenders. The result is a market with low barriers to theoretical entry but higher barriers to dependable commercial supply.

What licensing deals and settlement agreements affect these products?

No major current licensing transaction or patent settlement materially controls the U.S. commercial market for chloroquine phosphate or primaquine phosphate. Their commercial history predates the licensing structures common in newer specialty and biologic medicines.

The relevant agreements are more likely to be:

Government procurement contracts.
Regional distribution agreements.
Public-health supply arrangements.
Technology-transfer or contract-manufacturing agreements.
Product-registration partnerships.

Because there is no meaningful patent cliff remaining, a Paragraph IV settlement is unlikely to be a major market event. Any material commercial agreement would more likely concern supply access, geographic registration, or tender participation.

How does the patent estate compare with newer antimalarial drugs?

Factor	Chloroquine phosphate	Primaquine phosphate	Newer antimalarial
Core patent age	Expired for decades	Expired for decades	Often active or recently expired
U.S. NCE exclusivity	None	None	Possible
Formulation differentiation	Low	Low to moderate	Moderate to high
Generic-entry risk	High	High	Variable
Pricing power	Very low	Low	Potentially higher
Clinical differentiation	Limited by resistance	Important for relapse prevention	Often stronger
Supply-chain sensitivity	High	High	Depends on product

Chloroquine has the weaker commercial outlook because resistance has reduced its malaria role. Primaquine has better clinical durability but remains constrained by low pricing, safety screening, and a relatively narrow indication.

What is the outlook for revenue exposure and investment risk?

Revenue exposure to either drug is unlikely to be material for a diversified pharmaceutical company unless the company specializes in established products or public-health tenders. The main financial outcomes are:

Stable low-margin sales from recurring government and endemic-market demand.
Periodic volume surges during outbreaks or stockpiling.
Margin pressure from tender competition.
Revenue losses from therapeutic substitution.
Upside from shortages affecting competing suppliers.
Limited value from patent litigation or exclusivity strategies.

Chloroquine has higher downside risk from declining clinical use. Primaquine has a steadier long-term role because relapse prevention remains clinically necessary in P. vivax and P. ovale management. Neither product supports a conventional branded-drug valuation based on patent duration.

Key Takeaways

Chloroquine phosphate and primaquine phosphate are separate legacy antimalarial products, not a single combination drug.
Both are effectively post-patent generic medicines with no meaningful remaining composition or NCE exclusivity.
Chloroquine demand is constrained by parasite resistance and therapeutic substitution.
Primaquine has a more durable clinical role in radical cure but requires G6PD risk management.
Neither drug has a transparent, separately reported global revenue figure.
Commercial performance depends on tenders, procurement, supply reliability, API costs, and regulatory compliance.
Paragraph IV litigation and patent settlements are low-probability commercial drivers.
The main competitive threats are artemisinin-based therapies for chloroquine and tafenoquine for primaquine.
Generic launch risk is high, but manufacturing and registration reliability can limit the number of dependable suppliers.
Primaquine has the stronger long-term demand profile, while chloroquine remains more exposed to volume erosion.

FAQs About Chloroquine Phosphate and Primaquine Phosphate

Is chloroquine phosphate still commercially relevant?

Yes, but its relevance is concentrated in malaria-susceptible regions, selected non-malarial uses, public-health stockpiles, and markets where low cost outweighs resistance concerns.

Is primaquine phosphate more valuable than chloroquine phosphate?

Clinically, primaquine has a stronger differentiated role because it prevents relapse from P. vivax and P. ovale. Commercially, it remains a low-priced generic and does not command specialty-drug economics.

Can a company obtain a new patent on a chloroquine or primaquine formulation?

A company could seek protection for a genuinely novel formulation, delivery system, combination, or manufacturing process. Such a patent would not restore exclusivity to the underlying active ingredient.

Does tafenoquine eliminate the market for primaquine?

No. Tafenoquine competes with primaquine but has its own access, diagnostic, labeling, and cost limitations. Primaquine remains widely relevant where it is available and affordable.

Are these drugs subject to FDA biologic or biosimilar competition?

No. Chloroquine phosphate and primaquine phosphate are small-molecule drugs. Their competition comes from generic oral products and alternative small-molecule antimalarials, not biosimilars.

References

U.S. Food and Drug Administration. (n.d.). Aralen (chloroquine phosphate) prescribing information. Drugs@FDA.
Centers for Disease Control and Prevention. (n.d.). Clinical guidance for malaria: Diagnosis and treatment. U.S. Department of Health and Human Services.
World Health Organization. (2023). World malaria guidelines. World Health Organization.
U.S. Food and Drug Administration. (2020, June 15). *FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	18
DailyMed Link:	CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE at DailyMed

Sponsor	Phase
University of California, San Francisco	Phase 2/Phase 3
Pan American Health Organization	Phase 2/Phase 3
Oswaldo Cruz Foundation	Phase 2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE	chloroquine phosphate; primaquine phosphate	TABLET;ORAL	014860-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE - Generic Drug Details

What are the generic sources for chloroquine phosphate; primaquine phosphate and what is the scope of patent protection?

Summary for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

Recent Clinical Trials for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

Anatomical Therapeutic Chemical (ATC) Classes for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

US Patents and Regulatory Information for CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

Chloroquine Phosphate and Primaquine Phosphate Market Dynamics, Patent Status, and Financial Trajectory